Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773181 | 0.96 | EDNRA (0.46) | EDNRAAGTR2AGTR1 | |
| SCHEMBL4767122 | 0.90 | EDNRA (0.60) | EDNRAAGTR1 | |
| SCHEMBL4770972 | 0.87 | EDNRA (0.59) | EDNRAAGTR1 | |
| SCHEMBL4764627 | 0.87 | EDNRA (0.52) | EDNRAAGTR2AGTR1 | |
| SCHEMBL4770094 | 0.86 | EDNRA (0.56) | EDNRAAGTR1 | |
| SCHEMBL4769621 | 0.85 | EDNRA (0.53) | EDNRAAGTR2AGTR1 | |
| SCHEMBL4771827 | 0.83 | EDNRA (0.58) | EDNRA | |
| SCHEMBL4769543 | 0.82 | EDNRA (0.56) | EDNRAAGTR2AGTR1 | |
| SCHEMBL4791671 | 0.79 | AGTR2 (0.51) | EDNRAAGTR2AGTR1 | |
| SCHEMBL4774374 | 0.77 | AGTR2 (0.57) | EDNRAAGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | claimed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | claimed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | claimed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR2 2/4885AGTR1 4/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR2 2/4885AGTR1 4/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR2 2/4885AGTR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.